期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新药时代造血干细胞移植治疗多发性骨髓瘤若干问题探讨 被引量：2

Several issues concerning hematopoietic stem cell transplantation in treatment of multiple myeloma in the new-drug era
原文传递
导出
摘要 新药时代,造血干细胞移植在多发性骨髓瘤(MM)综合治疗中的地位受到挑战。一些大规模、多中心、前瞻性的临床研究结果显示,对于年轻,具有遗传学高危因素,且有合适供者的MM患者,应首选异基因造血干细胞移植。对于不能接受异基因造血干细胞移植的患者,自体移植同样可以改善患者预后,延长患者生存期。因此,在新药时代,合理综合地运用新药与造血干细胞移植治疗,将会使患者最大程度获益。 With the wide usage of new drugs, the role of stem cell transplantation （SCT） has been challenged. The results of many large, multi-center and prospective clinical trial demonstrated that allo-SCT is a prior treatment for the young, with ge- netic high risk factor and proper donor. For the multiple myeloma patients unfit for allo-SCT,ASCT could also improve the prognosis and prolong the survival of patients. Hence ,reasonable performance of the HSCT and new drugs will benefit of the most multiple myeloma patients.
作者 李荣 侯健
机构地区 第二军医大学长征医院血液科全军骨髓瘤与淋巴瘤疾病中心
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2014年第2期115-117,126,共4页 Chinese Journal of Practical Internal Medicine
基金 上海市科委长三角科技攻关课题(12495810500) 上海市科委国际合作重点项目基金(11410708300)
关键词 多发性骨髓瘤 造血干细胞移植 multiple myeloma hematopoietic stem cell transplantation
分类号 R446.11 [医药卫生—诊断学]
  • 相关文献

参考文献2

二级参考文献17

  • 1Martinez-Lopez J, Blade J, Mateos M et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation [J]. Blood,2011,118:529 - 534.
  • 2Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myelo- ma treated with novel agents: analysis of 1175 patients[J]. Blood, 2011,117 : 3025 - 3031.
  • 3Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials [ J]. Blood,2011,118 : 1239.
  • 4San Miguel JF,Schlag R, Khuageva NK et at. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma [ J ]. N Engl J Med ,2008,359:906 -917.
  • 5Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated nmhiple myeloma: updated follow-up and impact of subsequent therapy in the phase II VISTA trial[J]. J Clin Oncol, 2010, 28 : 2259 - 2266.
  • 6Mateos MV, Oriol A, Martinez-Lopez J, et at. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with borte-zomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma : a randomised trial [J]. Lancet Oncol,2010 ,11:934 - 941.
  • 7Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalid- omide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial [ J ]. J Clin Onco1,2010 ,28 :5101 - 5109.
  • 8Bringhen S, Larocea A, Rossi D, et al. Efficacy and safety of once- weekly bortezomib in multiple myeloma patients [ J ]. Blood,2010, 116:4745 -4753.
  • 9Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study [ J ]. Lancet 0ncol,2011,12:431.
  • 10Delforge M,Terpos E, Richardson PG,et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-pred- nisone in the phase Ⅲ VISTA trial in multiple myeloma [ J ]. Eur J. Haematol,2011,86:372.

共引文献10

同被引文献35

  • 1Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibitionin human multiple mye- loma cells[J]. Proc Natl Acad Sci USA, 2002, 99(22) : 14374-14379.
  • 2Zheng B, Zhou R, Gong Y, et al. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemia cell lines[J]. Biochemical Int J Lab Hematol, 2012, 34(3):237-247.
  • 3Palumbo A, Ambrosini MT, Benevolo G, et al. Borte- zomib, melphalan, prednisone, and thalidomide for re- lapsed multiple myeloma [ J ]. Blood, 2007, 109 ( 7 ) : 2767 -2772.
  • 4Berenson JR, Yang HH, Sadler K, et al. Phase I/I1 trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma[J]. J Clin Oncol, 2006, 24(6) :937- 944.
  • 5Richardsom PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma [J]. Blood, 2014, 123(10) :1461-1469.
  • 6Chanhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS- 341 resistance in lymphoma cells [ J ]. Cancer Res, 2003,63(69) :6174-6177.
  • 7Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein[J]. Blood, 2008, 112(6) :2489-2499.
  • 8Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis [ J. Cancer Cell, 2007, 411 (4) :349-360.
  • 9Teru Hideshima, Klans Podar, Dharminder Chauhan, et al. p38 MAPK inhibition enhances PS-341 (borte- zomib)-induced cytotoxicity against multiple myeloma cells [ J ], Oncogene, 2004, 23 (54) : 8766-8776.
  • 10Wang BD, Kline CL, Pastor DM, et al. Prostate apop- tosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network [J]. Mol Cancer, 2010, 430(9) :1186-1476.

引证文献2

中国实用内科杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部